Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vitro selection of resistance to sofosbuvir in HCV replicons of genotype-1 to -6.

Antiviral therapy - 1 Jan 2017

Xu Simin, Doehle Brian, Rajyaguru Sonal, Han Bin, Barauskas Ona, Feng Joy, Perry Jason, Dvory-Sobol Hadas, Svarovskaia Evguenia S, Miller Michael D, Mo Hongmei

Abstract excerpt

BACKGROUND: Sofosbuvir is a nucleoside analogue inhibitor of the HCV NS5B polymerase approved for treatment of HCV-infected patients in combination with ribavirin or with other antivirals. It has activity against all genotypes of HCV. Resistance to sofosbuvir in genotype-1 and -2 HCV is conferred by the S282T substitution in NS5B. METHODS: To begin to define the correlates of resistance to sofosbuvir in other...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genome, Viral

Share to Hepatitis C

Share to Sofosbuvir

Share to Structure-Activity Relationship

Share to Viral Nonstructural Proteins

Share to Virus Replication

Source

Identifiers

PMID: 28248189
DOI: 10.3851/IMP3149

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vitro selection of resistance to sofosbuvir in HCV replicons of genotype-1 to -6.PMID 28248189Read ↗

Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials.Semantic proximity Read ↗

Construction and characterization of a new hepatitis C virus genotype 6a subgenomic replicon that is prone to render the sofosbuvir resistance.Semantic proximity Read ↗

Identification of a novel replication-competent hepatitis C virus variant that confers the sofosbuvir resistance.Semantic proximity Read ↗

Barrier-Independent, Fitness-Associated Differences in Sofosbuvir Efficacy against Hepatitis C Virus.Semantic proximity Read ↗

Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvirSemantic proximity Read ↗

Characterization of resistance to the nonnucleoside NS5B inhibitor filibuvir in hepatitis C virus-infected patients.Semantic proximity Read ↗

Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: <i>In Vitro</i> Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life CycleSemantic proximity Read ↗

HCV Genotype 6a Escape From and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models.Semantic proximity Read ↗

Studies on hepatitis C virus resistance to inhibitors in replicon systems.Semantic proximity Read ↗

Selecting and characterizing drug-resistant hepatitis C virus replicon.Semantic proximity Read ↗

Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796.Semantic proximity Read ↗

Robust HCV Genotype 3a Infectious Cell Culture System Permits Identification of Escape Variants With Resistance to Sofosbuvir.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.